Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

77
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
77
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

71
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
71
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

129
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
129
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

78
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
78
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

186
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
186
Methods of Medium Optimization01:28

Methods of Medium Optimization

45
Optimizing growth media enhances microbial proliferation and maximizes product yield. Statistical experimental design methodologies provide structured and reproducible approaches, offering progressively higher levels of robustness and efficiency.The One-Factor-at-a-Time (OFAT) MethodThe One-Factor-at-a-Time (OFAT) method involves adjusting a single variable while keeping all others constant. However, it cannot detect interactions between variables, often leading to suboptimal outcomes when...
45

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I dose-ascending, safety, and pharmacokinetics study of APC148, a novel metallo-β-lactamase inhibitor, in healthy volunteers.

Antimicrobial agents and chemotherapy·2026
Same author

Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR.

Journal of medicinal chemistry·2026
Same author

Comparison of BAFF and type I IFN activity in blood and placenta in SLE and healthy pregnancies.

Lupus science & medicine·2026
Same author

Dabigatran Concentrations in an Actively Breastfeeding Mother-Infant Dyad: Extending the Evidence for Oral Thromboprophylaxis Postpartum.

American journal of hematology·2026
Same author

Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression.

Journal of clinical psychopharmacology·2026
Same author

Early clinical pharmacology evaluation of the novel anti-inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions.

British journal of clinical pharmacology·2026

Related Experiment Video

Updated: Mar 29, 2026

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
06:24

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

10.8K

Optimizing DMPK Properties: Experiences from a Big Pharma DMPK Department.

Anna-Karin Sohlenius-Sternbeck1, Juliette Janson, Johan Bylund

  • 1DMPK & Bioanalysis, Medivir AB, SE-141 44 Huddinge, Sweden. annakarin.sternbeck@gmail.com.

Current Drug Metabolism
|December 15, 2015
PubMed
Summary

Optimizing drug development involves understanding drug metabolism and pharmacokinetics (DMPK) and physicochemical properties. Integrating these insights accelerates compound optimization and informed decision-making in drug discovery.

More Related Videos

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
09:28

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

9.4K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

6.2K

Related Experiment Videos

Last Updated: Mar 29, 2026

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
06:24

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

10.8K
Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
09:28

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

9.4K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

6.2K

Area of Science:

  • Pharmacology and Drug Discovery
  • Medicinal Chemistry
  • Biotechnology

Background:

  • Drug disposition relies on drug properties, body interactions, and biological barriers.
  • Achieving therapeutic effects requires drugs to reach target sites at adequate concentrations.
  • This review focuses on the role of drug metabolism and pharmacokinetics (DMPK) and physicochemical properties in compound optimization at AstraZeneca.

Purpose of the Study:

  • To present key assays for evaluating DMPK properties of new chemical entities.
  • To guide the interpretation of assay outcomes for effective compound optimization.
  • To describe an integrated approach for predicting drug fate in humans early in discovery.

Main Methods:

  • Utilized assays for solubility, LogD, permeability, and metabolic stability in early drug discovery.
  • Implemented high-throughput methods for efficient bioanalysis and sample handling.
  • Integrated in vitro data for early "dose to man" predictions, refined with in vivo pharmacokinetic (PK) and pharmacodynamic (PD) data.

Main Results:

  • Developed a streamlined workflow for DMPK activities from lead identification to candidate selection.
  • Achieved cost-effective and efficient optimization of chemical series.
  • Facilitated informed decision-making throughout the drug discovery project lifecycle.

Conclusions:

  • A robust DMPK workflow enhances efficiency and cost-effectiveness in drug development.
  • Early and integrated assessment of DMPK properties is crucial for successful compound optimization.
  • Informed decision-making, supported by comprehensive data, drives successful drug candidate selection.